Skip to main content
SpringerLink
Log in

Traitement des patients réfractaires primaires ou en première rechute de lymphomes hodgkiniens

  • Chapter
Actualités thérapeutiques dans les lymphomes

  • 541 Accesses

Résumé

Nous parlerons essentiellement des rechutes de lymphomes hodgkiniens (LH) classiques qui représentent 95 % des cas, les formes nodulaires à prédominance lymphocytaire ou (LHNPL) seront traitées dans un paragraphe à part à la fin du chapitre.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. André M, Brice P, Cazals D, et al. (1997) Results of 3 courses of ABVD with subtotal nodal irradiation in 189 patients with nodal Hodgkin’s disease (stage I, II, IIIA). Hematol Cell Ther 39: 59–65

    Article  PubMed  Google Scholar 

  2. Duggan DB, Petroni GR, Johnson JL, et al. (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21: 607–14

    Article  PubMed  CAS  Google Scholar 

  3. Diehl V, Franklin J, Pfreundschuh M, et al. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348: 2386–95

    Article  PubMed  CAS  Google Scholar 

  4. Ferme C, Eghbali H, Meerwaldt JH, et al. (2007) Chemotherapy plus involved-field radiation in early stage Hodgkin’s disease. N Engl J Med 357: 1916–27

    Article  PubMed  CAS  Google Scholar 

  5. Vivani S, Zinzani PL, Rambaldi A, et al. (2011) ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 365: 203–12

    Article  Google Scholar 

  6. André M, Henry-Amar M, Pico JL, et al. (1999) Comparison of high-dose therapy and ASCT with conventional therapy for Hodgkin’s disease induction failure: a case-control study. J Clin Oncol 17; 222–9

    PubMed  Google Scholar 

  7. Lohri A, Barnett M, Fairey RN, et al. (1991) Outcome of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1980. Blood 77: 2292–8

    PubMed  CAS  Google Scholar 

  8. Brice P, Bastion Y, Diviné M, et al. (1996) Analysis of prognostic factors after the first relapse of Hodgkin’s disease in 187 patients. Cancer 78: 1293–99

    Article  PubMed  CAS  Google Scholar 

  9. Josting A, Rueffer U, Franklin J, et al. (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 96: 1280–6

    PubMed  CAS  Google Scholar 

  10. Crump M, Smith AM, Brandwein J, et al. (1993) High-dose etoposide and melphalan and ABMT for patients with advanced Hodgkin’s disease, importance of disease status at transplant. J Clin Oncol 11: 704–11

    PubMed  CAS  Google Scholar 

  11. Akpek G, Abinder RF, Piantadosi A, et al. (2001) Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol 19: 4314–21

    PubMed  CAS  Google Scholar 

  12. Brice P, Bouabdallah R, Moreau P, et al. (1997) Prognostic factors for survival after high-dose therapy and ASCT for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French Registry. Bone Marrow Transplant 20: 21–6

    Article  PubMed  CAS  Google Scholar 

  13. Moskowitz CH, Nimer SD, Zelenetz AD, et al. (2001) A 2 step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97: 616–23

    Article  PubMed  CAS  Google Scholar 

  14. Josting A, Franklin J, Sieber M, et al. (2002) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. J Clin Oncol 20: 220–31

    Article  Google Scholar 

  15. Morschhauser F, Brice P, Ferme C, et al. (2008) Risk-adapted salvage treatment with single or double autologous stem-cell transplantation for first relapsing/refractory Hodgkin lymphoma: results of the prospective multicenter H96 trial. J Clin Oncol 26: 5780–7

    Google Scholar 

  16. Filmont JE, Gisselbrecht C, Cuenca X, et al. (2007) The impact of pre-and posttransplantation PET using 18-FDG on poor-prognosis lymphoma patients undergoing autologous stem-cell transplantation. Cancer 110: 1361–9

    Article  PubMed  Google Scholar 

  17. Rodriguez J, Rodriguez MA, Fayad L, et al. (1999) ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin’s disease. Blood 93: 3632–6

    PubMed  CAS  Google Scholar 

  18. Santoro A, Magagnoli M, Spina M, et al. (2007) Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 92: 35–41

    Article  PubMed  CAS  Google Scholar 

  19. Fermé C, Mounier N, Diviné M, et al. (2002) Intensive salvage chemotherapy with high-dose chemotherapy for patients with advanced HD in relapse or failure after initial chemotherapy: results of the GELA H89 trial. J Clin Oncol 20: 467–75

    Article  PubMed  Google Scholar 

  20. Sibon D, Ertaut M, Al Nawakil C, et al. (2011) Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. B J Haematol 153: 191–8

    Article  CAS  Google Scholar 

  21. Bartlett NL, Niedzwiecki D, Johnson JL, et al. (2007) Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 18: 1071–9

    Article  PubMed  CAS  Google Scholar 

  22. Josting A, Nogova L, Franklin J, et al. (2005) Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 23: 1522–9

    Article  PubMed  Google Scholar 

  23. Moulin-Romsee G, Hindié E, Cuenca X et al. (2010) 18F-FDG PET/CT bone:bone marrow findings in Hodgkin’s lymphoma may circumwent the use of bone marrow trephine biopsy at diagnostic staging. Eur J Nucl Mol Imaging 36: 1095–105

    Article  Google Scholar 

  24. Dann EJ, Bar-Shalom R, Tamir A, et al. (2010) A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin’s lymphoma. Haematologica 95: 1198–206

    Article  PubMed  Google Scholar 

  25. Moskowitz AJ, Yahalom J, Kewalramani T, et al. (2010) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory HL. Blood 116: 4934–7

    Article  PubMed  CAS  Google Scholar 

  26. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. (2012) Normalisation of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves EFS in patients with HL. Blood 119: 1665–70

    Article  PubMed  CAS  Google Scholar 

  27. Bierman PJ, Bagin RG, Jagannath S, et al. (2001) Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol 19: 4314–21

    Google Scholar 

  28. Sureda A, Arranz R, Iriondo E, et al. (2001) ASCT for Hodgkin’s disease: results and prognostic factors in 494 patients from the Spanish cooperative group. J Clin Oncol 19: 1395–404.

    PubMed  CAS  Google Scholar 

  29. Schmitz N, Pfistner B, Sextro M, et al. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with ASCT for relapsed chemosensitive Hodgkin’s disease: a randomized trial. Lancet 325: 2065–71

    Article  Google Scholar 

  30. Josting A, Muller H, Borchman P, et al. (2010) Dose intensify chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol 28: 5074–80

    Article  PubMed  Google Scholar 

  31. Feugier P, Labouyrie E, Djeridane M, et al. (2004) Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood 104: 2675–81

    Article  PubMed  CAS  Google Scholar 

  32. Nogova L, Reineke T, Brillant C, et al. (2008) Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26: 434–9

    Article  PubMed  Google Scholar 

  33. Biasoli I, Stamatoullas A, Meignin V, et al. (2010) Nodular lymphocyte-predominant Hodgkin lymphoma a long-term study and analysis of transformation to DLBCL in a cohort of 164 patients. Cancer 16: 631–9

    Article  Google Scholar 

  34. Al-Mansour M, Connors JM, Gascoyne R, et al. (2010) Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 28: 793–9

    Article  PubMed  Google Scholar 

  35. Rehwald U, Schulz H, Reiser M, et al. (2003) Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 101: 420–4

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’hémato-oncologie, hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75010, Paris, France

    P. Brice

Authors
  1. P. Brice
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Brice .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Paris

About this chapter

Cite this chapter

Brice, P. (2013). Traitement des patients réfractaires primaires ou en première rechute de lymphomes hodgkiniens. In: Actualités thérapeutiques dans les lymphomes. Springer, Paris. https://doi.org/10.1007/978-2-8178-0371-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0371-5_3

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0370-8

  • Online ISBN: 978-2-8178-0371-5

Publish with us

Policies and ethics

Search

Navigation